Results 31 to 40 of about 93,929 (247)
Homeobox B13 activates the hypoxia-inducible factor 1 pathway through histone lactylation thereby reprogramming lipid metabolism and promoting sorafenib resistance in hepatocellular carcinoma. [PDF]
J Cell Commun SignalLactylation‐mediated metabolism reprogramming in HCC sorafenib resistance. In sorafenib‐resistant hepatocellular carcinoma (HCC) cells, lactate accumulation drives histone H3 lysine 18 lactylation (H3K18la). This modification is specifically enriched in the promoter region of homeobox B13 (HOXB13), activating HOXB13 transcription and upregulating its ...
Xie Q +5 more
europepmc +2 more sources
Frontiers in Pharmacology, 2022 Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib ...
Zhi-Yong Liu +31 more
doaj +1 more source
The Oncologist, EarlyView., 2021 Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth +10 more
wiley +1 more source
BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib. [PDF]
PLoS ONE, 2013 The multikinase inhibitor, sorafenib (Nexavar®, BAY43-9006), which inhibits both the Raf/MEK/ERK pathway and several receptor tyrosine kinases (RTKs), has shown significantly therapeutic benefits in advanced hepatocellular carcinoma (HCC).
Wei-Chien Huang +10 more
doaj +1 more source
BMC Cancer, 2018 Background Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications.
Shuling Chen +9 more
doaj +1 more source
Journal of Experimental & Clinical Cancer Research, 2023 Background Sorafenib resistance is a key impediment to successful treatment of patients with advanced hepatocellular carcinoma (HCC) and recent studies have reported reversal of drug resistance by targeting ferroptosis. The present study aimed to explore
Yan Li +13 more
doaj +1 more source
Cancer Biology & Medicine, 2022 Objective: Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC). Unfortunately, most patients with HCC do not respond to sorafenib, mainly because of the frequent development of drug resistance.
Leyi Yao +12 more
doaj +1 more source
Frontiers in Pharmacology, 2020 PurposeTo investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC).Materials and MethodsThis retrospective study examined 50 ...
Ying Wu +18 more
doaj +1 more source
Tyrosine kinase inhibitors for the therapy of anaplastic thyroid cancer [PDF]
, 2015 Anaplastic thyroid cancer (ATC) is often incurable so new therapeutic approaches are needed. Tyrosine kinases inhibitors (such as imanitib, sunitinib or sorafenib) are under evaluation for the treatment of ATC.
Bond JA +11 more
core +1 more source
PLoS ONE, 2021 Background and aimAs a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems.
Luping Gao +8 more
doaj +1 more source